Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Roche Pharmaceuticals A/S

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.1% 1.1%   Bankruptcy risk   2.0% 2.1% 2.1% 0.8% 0.5% 0.6% 7.8% 7.7%   Credit score (0-100)   70 69 67 90 98 95 9 9   Credit rating   BBB BBB BBB A AA A B B   Credit limit (mDKK)   0.0 0.0 0.0 14.9 20.5 17.7 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1.0 Income statement (mDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   808 718 702 733 786 761 761 761   Gross profit   153 126 127 133 149 145 0.0 0.0   EBITDA   34.7 22.4 11.0 22.3 35.5 42.9 0.0 0.0   EBIT   34.7 22.4 11.0 22.3 35.5 42.9 0.0 0.0   Pre-tax profit (PTP)   30.2 21.8 12.3 22.3 35.8 43.8 0.0 0.0   Net earnings   30.2 21.8 12.3 16.3 19.6 36.5 0.0 0.0   Pre-tax profit without non-rec. items   34.7 22.4 11.0 22.3 35.8 43.8 0.0 0.0     See the entire income statement 1.0 Balance sheet (mDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.2 14.2 15.7 0.0 0.0   Shareholders equity total   138 160 127 143 163 140 136 136   Interest-bearing liabilities   0.0 0.0 0.0 126 135 127 0.0 0.0   Balance sheet total (assets)   324 352 378 354 390 358 136 136   Net Debt   0.0 0.0 0.0 126 135 127 -136 -136     See the entire balance sheet 1.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   808 718 702 733 786 761 761 761   Net sales growth   -10.0% -11.1% -2.3% 4.4% 7.2% -3.1% 0.0% 0.0%   Gross profit   153 126 127 133 149 145 0.0 0.0   Gross profit growth   -7.9% -17.5% 0.6% 4.9% 12.1% -2.6% -100.0% 0.0%   Employees   120 121 121 110 103 97 0 0   Employee growth %   -1.6% 0.8% 0.0% -9.1% -6.4% -5.8% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   324 352 378 354 390 358 136 136   Balance sheet change%   -10.4% 8.7% 7.6% -6.3% 9.9% -8.2% -62.1% 0.0%   Added value   34.7 22.4 11.0 22.3 35.5 42.9 0.0 0.0   Added value %   4.3% 3.1% 1.6% 3.0% 4.5% 5.6% 0.0% 0.0%   Investments   -38 0 0 0 14 2 -16 0   Net sales trend   -1.0 -2.0 -3.0 1.0 2.0 -1.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 5.0 5.0 0.0 0.0   1.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   4.3% 3.1% 1.6% 3.0% 4.5% 5.6% 0.0% 0.0%   EBIT %   4.3% 3.1% 1.6% 3.0% 4.5% 5.6% 0.0% 0.0%   EBIT to gross profit (%)   22.7% 17.8% 8.7% 16.8% 23.8% 29.5% 0.0% 0.0%   Net Earnings %   3.7% 3.0% 1.8% 2.2% 2.5% 4.8% 0.0% 0.0%   Profit before depreciation and extraordinary items %   3.7% 3.0% 1.8% 2.2% 2.5% 4.8% 0.0% 0.0%   Pre tax profit less extraordinaries %   4.3% 3.1% 1.6% 3.0% 4.6% 5.8% 0.0% 0.0%   ROA %   10.1% 6.6% 3.0% 6.1% 9.7% 11.9% 0.0% 0.0%   ROI %   11.5% 6.6% 3.0% 6.9% 12.4% 15.4% 0.0% 0.0%   ROE %   20.4% 14.6% 8.6% 12.0% 12.8% 24.1% 0.0% 0.0%   1.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   100.0% 100.0% 100.0% 40.4% 41.8% 39.0% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 28.5% 27.7% 28.4% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 28.5% 27.7% 28.4% -17.8% -17.8%   Net int. bear. debt to EBITDA, %   0.0% 0.0% 0.0% 562.6% 380.5% 295.4% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 87.6% 82.9% 90.7% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 0.1% 0.1% 0.4% 0.0% 0.0%   1.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   0.0 0.0 0.0 0.9 1.1 0.9 0.0 0.0   Current Ratio   0.0 0.0 0.0 1.7 1.7 1.6 0.0 0.0   Cash and cash equivalent   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   1.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 59.6 44.5 75.6 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 48.3% 47.8% 44.9% 17.8% 17.8%   Net working capital   0.0 0.0 0.0 146.3 157.7 125.4 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 20.0% 20.1% 16.5% 0.0% 0.0%   1.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   7 6 6 7 8 8 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0